MedTrace Logo

Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy

NCT05902247 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-06-13

No results posted yet for this study

Summary

225Ac-PSMA I\&T is a radiopharmaceutical for therapy of prostate cancer. PSMA is overexpressed on prostate cancer cells. Actium-225 is an alpha emitting radionuclide. When PSMA I\&T is labelled with Actium-225, it can be applied as therapy for prostate cancer.

Conditions

  • Prostatic Neoplasms, Castration-Resistant

Interventions

RADIATION

Radionuclide Therapy

To evaluate the tolerability and safety of 225Ac-PSMA I\&T in patients with metastatic prostate cancer

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-29
Primary Completion
2025-12-29
Completion
2025-12-29

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05902247 on ClinicalTrials.gov